cyrilzakka/clinical-trials huggingface dataset:
A Study of Child Injury Based on Data Mining

A comprehensive pediatric injury burden assessment is an essential foundation for formulating injury prevention strategies and improving emergency care for injured children. Although the hospital-based passive surveillance of national injury surveillance system of medical and health institutions has been well-established in China, the monitoring points of hospitals were not stratified according to children's hospital. Aim of the project is to collect epidemiological and clinical data to describe causes, clinical features and outcomes of pediatric injuries at a Children's Hospital in Shanghai, China. The project intends to establish a method for collecting and analyzing high quality data of child injury using data mining based on the hospital information system.

Injuries are a leading cause of death for infants and children around the world. According to the Haddon Injury Control Model, 90 percent of injuries are both predictable and preventable. Injuries are preventable, not "accidents". All unintentionally and intentionally injured children first visit to the emergency department are recruited in the study. Children's Hospital of Fudan University with a Regional Pediatric Trauma Centre is also the first Pediatric Injury Prevention Center established in China. We conduct a prospective cohort study to investigate the epidemiology, clinical course, and outcomes of the injured child first visit to the emergency department, which expected to serve as evidence of injury prevention and promising practices. In the study, we collect and analyze high quality data of child injury based on data mining.

Eligibility Criteria:
Inclusion Criteria:

All pediatric patients between the ages of 0-18 years newly diagnosed with injuries in the emergency department，and recorded ICD-10 diagnosis codes from V01 to X39

Exclusion Criteria:

Patients who were dead on arrival to the emergency department are not included.
Study of LJP 394 (Abetimus Sodium) in Lupus Patients

The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP 394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.

STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804.

Eligibility Criteria:
Inclusion Criteria:

* Males or females between 12 and 70 years old.
* Diagnosis of Systemic Lupus Erythematosus (SLE)
* Females must be non-pregnant and non-lactating. Females must agree to use adequate birth control methods during the course of the study.
* Ability to have weekly intravenous (IV) administration of study drug.

Exclusion Criteria:

* Prior exposure to abetimus sodium within 6 months prior to screening.
* Patients not on stable medications for 30 days prior to screening.
* Patients with acute or chronic infections.
Effect of Maitland Mobilization With Low Level Laser Therapy in Treatment of Patients With Knee Osteoarthritis

Background: Osteoarthritis is a common cause of chronic pain and disability in elderly people.

Objective: To evaluate the efficacy of low-level laser therapy (LLLT) in combination with Maitland mobilization and conventional physical therapy in patients with chronic knee osteoarthritis.

Design: Pre-test post-test randomized control trial.

Knee OA is associated with pain and disability, high treatment costs, decreased productivity, and absence from work and thus has a substantial and growing burden on society Objective: To evaluate the efficacy of low-level laser therapy (LLLT) in combination with Maitland mobilization and conventional physical therapy in patients with chronic knee osteoarthritis.

Participants: Seventy five subjects of both genders with age range from 50 to 65 years, with proven bilateral knee OA diagnosed and referred by orthopaedist were recruited for the study and randomly assigned into three groups.

Eligibility Criteria:
Inclusion Criteria:

Subjects with proven bilateral Knee OA with age range 50- 65 years according to the American College of Rheumatology criteria.

2- Only patients with X-ray stages II and III osteoarthritis selected according to Kellgren \& Lawrence classification system.

3- BMI equal to or less than 30 . 4- Patients with Knee pain lasted at least 6 months with intensity at least 3 on VAS scale in activities such as going up-and downstairs, sitting and squatting.

5- Patients with normal mental state. 6- Patients who are not participating in physical therapy in the recent 3 months.

.

Exclusion Criteria:

1. Patient with history of gout, infection, tumour, autoimmune diseases, trauma or other causes of knee pain or knee deformities.
2. Patient with neurologic dysfunction, or with history of chronic disease that may affect the study.
3. Patient with history of knee intra-articular injection in the past 6 months.
Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

PD-1 inhibitors have become the standard treatment for advanced hepatocellular cancer, while targeted drugs such as sorafenib and lenvatinib are the first-line standard treatment for hepatocellular cancer. Recent studies have shown that PD-1 inhibitors combined with targeted drugs can improve the efficacy of hepatocellular cancer.To clear the joint treatment in patients with advanced hepatocellular cancer (HCC) efficacy and evaluate its safety, we proposed to carry out the PD - 1 inhibitor (Toripalimab, JS001) joint anti-angiogenesis small molecules targeting drug anlotinib for clinical research,at the same time, based on joint solution of NGS platform testing to predict the curative effect, bring benefit for the long-term survival of patients with hepatocellular cancer (HCC).


Eligibility Criteria:
Inclusion Criteria:

1. Histological or cytological diagnosis of hepatocellular cancer;
2. At least one measurable lesion was assessed according to RECIST1.1 criteria.
3. Age from 18 to 75,ECOG physical strength score reaches 0-2;
4. After first-line targeted therapy, it was assessed as advanced or intolerant according to RECIST1.1 criteria.
5. Child-pugh grade A or B for liver function;
6. Bone marrow function was basically normal: neutrophils \> 1.5x 10\^9/L, platelets \> 75 x10\^9/L;
7. Adequate renal reserve: creatinine \<130 mol/L;
8. Centerless dysfunction, chest pain (medically uncontrollable), no myocardial infarction within 12 months prior to study initiation;
9. Estimated survival ≥3 months;
10. Signed the informed consent.

Exclusion Criteria:

1. Previous application of PD-1 inhibitor and anlotinib;
2. Secondary malignant tumors or other tumors (except superficial skin cancer and localized low-grade malignant tumors) occurring within 3 years prior to the start of the study;
3. Metastasis of the brain or meninges;
4. Imaging findings indicated that the tumor was involved in important blood vessels or that the researchers had assessed that it might lead to fatal bleeding during follow-up;
5. Bleeding events at any site ≥CTCAE level 3 occurred 4 weeks before medication, and there were unhealed wounds, ulcers or fractures;
6. The time of occurrence of arteriovenous thrombosis, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, within 6 months before enrollment;
7. Untreated intestinal obstruction or subobstruction that cannot eat or affect systemic administration;
8. Patients with active infection or other possible disorders receive inflammatory infections under planned management;
9. Have a history of uncontrolled substance abuse or mental disorders;
10. In the judgment of the investigator, patients with concomitant diseases that may seriously endanger their own safety or may affect the completion of the study;
11. Participated in other clinical trials;
12. Pregnant and nursing women;
Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System

Flow disruption is a new endovascular approach for treatment of both ruptured and unruptured intracranial aneurysms, which involves placement of an endosaccular device (WEB) which modifies the blood flow at the level of the neck and induces intraaneurysmal thrombosis. The WEB was designed to treat wide-neck bifurcation aneurysms. This observational study will collect data about the routine practice in one center of using the WEB in ruptured and unruptured intracranial aneurysms. The primary objective is to evaluate its efficacy by assessing the anatomic outcome during follow-up.


Eligibility Criteria:
Inclusion Criteria:

1. Patient is at least 18 years old.
2. Patient is capable to undergo general anaesthesia.
3. Patient must sign and date the informed consent form prior to data registration. If patient is not able to give informed consent for himself/herself, a legally authorized representative must give informed consent on his/her behalf.
4. Patient has a ruptured or unruptured intracranial aneurysm requiring endovascular treatment.
5. Aneurysm with dome-to-neck ratio ≥ 1.
6. Aneurysm size favourable for WEB implantation (aneurysm width \< 10 mm or aneurysm width \> 3mm).

Exclusion Criteria:

1. Patient is pregnant.
2. Patient has renal insufficiency (GRF \< 45 ml/min/1.73 m2).
3. Patient is unable to comply with the study protocol (e.g. no permanent address, known to be non-compliant or presenting an unstable psychiatric history).
Long Term Follow-up After Embolization of Brain Arteriovenous Malformations

The time-frame and the follow-up elements after embolization of brain arteriovenous malformations are not standardized. Therefore, few reliable follow-up data are available for these patients. This study aims at collecting standardized long term data for these patients.


Eligibility Criteria:
Inclusion Criteria:

* arteriovenous malformation
* age \> 18 years old

Exclusion Criteria:

* none
Maintenance of Anaesthesia With Sevoflurane Versus Propofol and the Occurrence of Postoperative Headache.

Postoperative headache is a major issue after general anaesthesia and surgery. The aim of this study is to investigate the possible difference in the occurrence of postoperative headache when general anaesthesia is maintained with propofol, which is supposed to have protective effects on migraine patients, versus sevoflurane.

Postoperative headache is a major issue after general anaesthesia and surgery. The aim of this study is to investigate the possible difference in the occurrence of postoperative headache when general anaesthesia is maintained with propofol, versus sevoflurane. Propofol acts throught a GABA, and is known to have a therapeutic effect on migraine patients with accute attacts. However, its role on postoperative headache has not been studied, when used for maintainance of anaesthesia, this study aims to investigate the occurrence of headache after anaesthesia and surgery, when patients receive randomly two different anaesthetics: propofol and sevoflurane.

Eligibility Criteria:
Inclusion Criteria:

* ASA I-III
* scheduled operation under general anaesthesia
* operations \<4 hours
* minorgynaecological operatios (leiomyomectomy)
* hernia repair
* arthroscopic procedurs
* minor orthopaedic operations without the use of tourniquet or cement
* saphenectomy
* minor urologic operations
* minor other operations of general surgery

Exclusion Criteria:

* age \<18 and \>65 years old
* ASA\>III
* Diseases of the central nervous system (ie Parkinsons's disease, Multiple sclerosis, previous ischaemic attack, hydrocephalus, seizure disorder, etc)
* Psychosis under medication
* Cognitive impairement or/and inability to fill in the questionaires
* Allergy or contraindication to the study protocol included drugs
* Operations of more than 4 hours duration
* Head and neck procedures, procedures with neck extension (eg thyroidectomy), ENT procedures
* renal impairement
* hepatic impairement
* patient refusal
Orofacial Evaluation in Women With Rheumatoid Arthritis

Rheumatoid arthritis (RA) can affect any synovial joint. Unlike the hand, ever so valued in the physical examination of patients with RA, the joints in the area of the jaw and neck may also be affected in this disease and have their involvement usually underdiagnosed. There are few studies evaluating the incidence of orofacial alteration in the examination as well as the correlation between bite force (BF) and clinical and functional parameters in these patients. The aim of our study was to chacacterize the orofacial alterations in RA patients, correlate the results of the orofacial evaluation with clinical and disease activity parameters, and correlate the bite force with the hand strenght.


Eligibility Criteria:
Inclusion Criteria:

RA group:

* rheumatoid arthritis (American College of Rheumatology)

Control group:

* healthy

Exclusion Criteria:

* edentate be total, have been subjected to surgical procedure in the last six months in the region of the hands or oral maxillo facial
Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With Hepatic and Post Hepatic Jaundice

Investigating the efficacy, safety, and molecular mechanism of N-acetylcysteine supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice.


Eligibility Criteria:
Inclusion Criteria:

* Patients age 18-70 years old.
* Patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dL.

Exclusion Criteria:

* Pregnancy.
* Nursing mothers.
* Patients with increased indirect bilirubin level.
* Patients who have Gilbert syndrome or Crigler Najjar syndrome.
* Patients with Child Paugh C score (10-15 point).
* History of known hypersensitivity to N-acetylcysteine.
Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

Randomized, double-blinded study that will evaluate the tolerability, safety, and flow rates of different solutions subcutaneously (SC) infused and preceded by human recombinant hyaluronidase (hylenex) 150 units.

In Stage 1, the comparison will be Normal Saline (NS) solution to Lactated Ringer's (LR) solution. Each subject will receive 500 milliliters (mL) of solution, consisting of NS in one thigh and LR in the other thigh. Immediately prior to the infusions, each thigh will have 150 units of hylenex.

In Stage 2, the comparison will be NS solution and buffered NS solution.

This Phase IV, randomized, double-blinded study in volunteer subjects to evaluate the tolerability, safety, and flow rates of different solutions subcutaneously (SC) infused and preceded by human recombinant hyaluronidase (hylenex) 150 units. The study will be conducted in two sequential stages.

In Stage 1, the comparison will be NS solution to LR solution. Each subject will receive simultaneous SC infusions of 500 mL (from a 500 mL bag) of solution in each anterior thigh, consisting of NS in one thigh and LR in the other thigh. The thighs (left vs. right) to receive NS and LR will be randomized and double blinded. Immediately prior to the infusions, each thigh will have 150 units of hylenex simultaneously injected.

Tolerability will be assessed based on the subject's self-assessment of discomfort on a visual analog scale (VAS). Safety will be assessed by physical examination targeted at infusion sites, vital signs, and adverse events. The amount of fluid infused will be assessed by weighing the infusion bag, fluid and tubing at designated time points, and allowing the determination of flow rate.

Stage 2 will be conducted only if the observed Stage 1 VAS mean maximum pain score is at least 25 mm higher for one solution compared to the other. Stage 2 will evaluate the tolerability, safety, and flow rates of subcutaneously infused NS solution and buffered NS solution.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female, 18 to 60 years of age.
2. Intact normal skin without in the areas intended for infusion.
3. No fluid intake for 12 hours prior to the start of the study infusion.
4. Vital signs (Blood Pressure (BP), Heart Rate (HR), Respiratory Rate (RR)) within normal range.
5. Metabolic panel within normal range.
6. A negative urine or serum pregnancy test.
7. Signed, written Institutional Review Board (IRB)-approved informed consent.

Exclusion Criteria:

1. Lower extremity edema.
2. Lower extremity pathology that could interfere with study outcome.
3. Rales on lung auscultation.
4. History of cardiovascular disease.
5. Allergy to hyaluronidase.
6. Allergy to bee or vespid venom.
7. Pregnancy or breast-feeding woman.
8. Use of any investigational drug or device within 30 days of enrollment.
Effects of Reiki Intervention During Labor on Pain, Fear, and Birth Experience

Childbirth is an important and often stressful experience for many women, and labor pain is common among women. While labor pain is a natural part of the birth process, its severity and management can have a significant impact on an expectant mother's overall health and birth experience. Studies examining the effects of Reiki on alleviating the pain and fear experienced by pregnant women during labor are limited. In this context, understanding the effects of Reiki practices in the birth process may be important for both clinical practice and future research.

Failure to control pain can cause the mother to experience fear and stress, which can increase the risk of complications during labor and indirectly have negative effects on the newborn. There is a strong association between labor pain and fear. Fear can increase the perception and intensity of pain, making the labor process more challenging and difficult to manage. This can negatively affect the mother's overall birth experience and complicate both the physical and emotional aspects of the birth process. A woman's birth experience also has an impact on her birth memory. A positive birth experience can cause a woman to evaluate the birth process as peaceful and satisfying, which positively shapes birth memory. The use of complementary and alternative therapies is increasing every year. Although Reiki has found application in various fields, there is no information in the available literature on its use in the management of labor pain. Reiki is a complementary treatment method based on the "energy approach" and is generally recognized as safe and without side effects.

Eligibility Criteria:
Inclusion Criteria:

Between the ages of 18 and 35, primiparous, singular primarily experiencing pregnancy, without risky pregnancy status (GDM, HT, etc.), during the birth week, literate Speaks and understands Turkish, 4 cm cervical dilatation

-

Exclusion Criteria:

To have attended a childbirth preparation course, Knowledge of coping with labor pain and fear of childbirth during pregnancy, Presence of chronic disease in the mother, Previous uterine surgery, Having become pregnant through assisted reproductive technologies, Hearing problems Being diagnosed with a known serious psychiatric illness.

-
A Trial of the Jejunal to Ileal Diversion Endoscopic Procedure (Side-to-Side Anastomosis)

This is a single center study to assess metabolic effects in subjects after a Jejunal to Ileal Diversion procedure was performed using colonoscopes.

The Jejunal to Ileal Diversion procedure is an adaptation of a biliopancreatic diversion with duodenal switch, which is a surgical procedure used to treat metabolic syndrome conditions. The small bowel diversion of the jejunum into the ileum by creating a single anastomosis just beyond the ligament of Trietz will be studied. Up to 15 eligible subjects will be enrolled into the trial. Enrollment will stop once 10 subjects have undergone the Jejunal to Ileal Diversion procedure.

Eligibility Criteria:
Inclusion Criteria:

* 18 to 65 years of age
* A BMI ≥ 30 kg/m2 and \< 50 kg/m2 If subject has Type 2 Diabetes
* HbA1c ≥ 6.5% and ≤ 9%
* Fasting plasma glucose greater than 110 mg/dl
* Treatment with up to 2 oral diabetic medications
* Able to understand and sign informed consent document
* If subject is female, she must commit to not becoming pregnant for 18 months and agree to use of contraceptives during this period

Exclusion Criteria:

* Any conditions for which endoscopy/colonoscopy would be contraindicated.
* Congenital or acquired anomalies of the GI tract, including atresias, stenosis or malrotation.
* Previous abdomino-pelvic surgery that may result in adhesions or anatomical changes that may interfere with placement of the GIW device.
* Diagnosis of Type 2 diabetes less than 6 months
* More than 2 oral diabetic medications
* Use of insulin
* If on metformin, history of polycystic ovarian syndrome (PCOS)
* Use of Dipeptidyl peptidase-4 (DPP-4) inhibitors
* Use of GLP-1 agonists
* Use of Use of alpha-glucosidase inhibitors
* Type 1 Diabetes
* Unable or unwilling to perform home blood glucose monitoring
* History of or suspected gastrointestinal disease (e.g. cirrhosis, inflammatory bowel disease)
* History of active malignancy (i.e. not in remission) with the exception of squamous or basal cell carcinoma of the skin
* Any blood coagulation disorder
* Implanted cardiac pacemaker, defibrillator or other implanted electric device - Ongoing systemic infection
* Chronic pancreatitis
* Chronic liver disease of any cause
* Poorly controlled psychiatric disease (e.g. ongoing major depression, schizophrenia, borderline personality, suicidality, psychosis)
* Any history of an eating disorder within the past 5 years
* Pre-existing severe comorbid cardio-respiratory disease (e.g. congestive heart failure, cardiac arrhythmia, coronary artery disease, chronic obstructive lung disease, pulmonary embolism)
* Uncontrolled hypertension (systolic BP \> 150 mm Hg or diastolic BP \> 100 mm Hg)
Egyptian Physical Therapists' Perceptions of Tele- Rehabilitation

The healthcare industry has undergone a significant transformation with the integration of digital technologies, and one of the notable advancements in this field is tele-rehabilitation. Tele-rehabilitation, a subset of telehealth, involves the use of digital platforms to deliver physical therapy services remotely. This innovative approach allows healthcare providers to extend their reach, offering therapy to patients who might otherwise face barriers to accessing care,tele-rehabilitation has been recognized for its numerous benefits. It enhances access to physical therapy services, particularly for individuals living in remote or underserved areas. By reducing the need for travel, tele-rehabilitation offers significant convenience to patients, enabling them to receive therapy in the comfort of their homes.


Eligibility Criteria:
* Must be a licensed physical therapist with at least 3 years of experience practicing in Egypt.
* Must be 25 years of age or older.
* Must have access to the internet and be able to complete an online survey.
* Available to complete all survey-related questions.

Exclusion Criteria:

* Not currently practicing as a physical therapist.
* Diagnosed with conditions that impair the ability to complete an online survey.